Valuation: KalVista Pharma

Market Cap 1.44B 1.26B 1.17B 1.07B 2.02B 139B 2.05B 13.93B 5.45B 67.87B 5.4B 5.28B 234B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.25B 1.16B 1.06B 2B 137B 2.03B 13.77B 5.39B 67.12B 5.34B 5.22B 232B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
3 months+38.96%
6 months+69.70%
Current year+67.18%
Current year 14.22
Extreme 14.22
27
1 year 10.41
Extreme 10.41
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
27
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2016-10-31
Chief Executive Officer 61 2024-03-05
President - 2026-06-10
Director TitleAgeSince
Chairman - 2026-06-10
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Issuer sale

Director

-17,000 0.0336%
6/11/26 Issuer sale

Chief Technology Officer

-478,560 0.9468%
6/11/26 Issuer sale

Director

-109,000 0.2156%

Financials

2024 2025
Net sales - 73.62M 64.5M 59.88M 55.03M 104M 7.1B 105M 713M 279M 3.48B 276M 270M 12.01B
Net income -127M -111M -103M -94.66M -178M -12.22B -181M -1.23B -480M -5.98B -475M -465M -20.66B -164M -144M -134M -123M -231M -15.85B -235M -1.59B -623M -7.76B -617M -603M -26.8B
Net Debt -203M -178M -165M -152M -286M -19.6B -290M -1.97B -770M -9.59B -762M -746M -33.12B -16.01M -14.03M -13.02M -11.96M -22.55M -1.54B -22.88M -155M -60.71M -756M -60.09M -58.79M -2.61B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. KALV Stock